Donaldson Capital Management LLC Acquires 326 Shares of Eli Lilly and Company (NYSE:LLY)

Donaldson Capital Management LLC raised its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,608 shares of the company's stock after buying an additional 326 shares during the period. Donaldson Capital Management LLC's holdings in Eli Lilly and Company were worth $19,498,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Mascagni Wealth Management Inc. bought a new position in shares of Eli Lilly and Company in the fourth quarter worth about $43,000. FPC Investment Advisory Inc. increased its stake in shares of Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after purchasing an additional 43 shares during the period. Prudent Man Investment Management Inc. bought a new position in shares of Eli Lilly and Company in the fourth quarter worth about $48,000. Compass Financial Services Inc bought a new position in shares of Eli Lilly and Company in the fourth quarter worth about $50,000. Finally, Capital A Wealth Management LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter worth about $63,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 0.4%

NYSE:LLY traded up $3.01 during trading hours on Thursday, hitting $811.62. 2,264,167 shares of the stock were exchanged, compared to its average volume of 3,649,721. The company's 50 day moving average is $773.53 and its two-hundred day moving average is $801.30. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The company has a market capitalization of $769.20 billion, a P/E ratio of 69.31, a price-to-earnings-growth ratio of 1.40 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same period in the prior year, the company posted $2.58 EPS. The firm's quarterly revenue was up 45.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.74%. The ex-dividend date of this dividend was Friday, May 16th. Eli Lilly and Company's dividend payout ratio is 48.82%.

Analysts Set New Price Targets

Several brokerages recently issued reports on LLY. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price target for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. UBS Group lowered their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Saturday, June 7th. Finally, Hsbc Global Res downgraded Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $1,011.37.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.